Related Experiment Video
Updated: May 11, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Κ-opioid receptor stimulation improves endothelial function in hypoxic pulmonary hypertension
1Department of Cardiology, Chengdu Medical College, Chengdu, P.R. China.
Plos One
|May 14, 2013
Summary
κ-opioid receptor stimulation with U50,488H improved endothelial function in rats with hypoxic pulmonary hypertension (HPH). This treatment reduced pulmonary arterial pressure and enhanced nitric oxide production, suggesting a therapeutic potential for HPH.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Pulmonary Medicine
Background:
- Hypoxic pulmonary hypertension (HPH) is a serious condition characterized by elevated pulmonary arterial pressure.
- Endothelial dysfunction plays a critical role in the development and progression of HPH.
- Targeting specific receptors like the κ-opioid receptor may offer novel therapeutic strategies.
Purpose of the Study:
- To investigate the effects of κ-opioid receptor stimulation using U50,488H on endothelial function in a rat model of HPH.
- To elucidate the underlying mechanisms by which U50,488H influences endothelial function and HPH parameters.
- To assess the potential of U50,488H as a therapeutic agent for HPH.
Main Methods:
- Induction of HPH in rats via chronic hypoxia (10% oxygen for 2 weeks).
- Administration of U50,488H and assessment of hemodynamic parameters (mPAP, RVP, RVHI).
- Evaluation of pulmonary artery endothelial function (acetylcholine-induced relaxation), nitric oxide synthase (eNOS, iNOS) activity and expression, NO production, total antioxidant capacity (T-AOC), gp91(phox) expression, and nitrotyrosine content.
Main Results:
- U50,488H administration significantly reduced mean pulmonary arterial pressure (mPAP) and right ventricular hypertrophy (RVHI) in HPH rats.
- Treatment with U50,488H improved endothelial-dependent relaxation in response to acetylcholine.
- U50,488H increased eNOS phosphorylation, serum NO content, and T-AOC, while enhancing eNOS activity and attenuating iNOS activity and oxidative stress markers (gp91(phox), nitrotyrosine).
Conclusions:
- κ-opioid receptor stimulation with U50,488H effectively improves endothelial function in rats with HPH.
- The beneficial effects are mediated by preserving eNOS activity, enhancing eNOS phosphorylation, downregulating iNOS activity, and exerting antioxidative/nitrative effects.
- U50,488H demonstrates potential as a therapeutic intervention for managing hypoxic pulmonary hypertension.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...